Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 5 | 13 | +0,06 % | ||
| AMGEN | 1 | 27 | +0,14 % | ||
| INCYTE | 1 | 25 | +1,48 % | ||
| REGENERON PHARMACEUTICALS | 1 | 22 | -0,35 % | ||
| COMPASS PATHWAYS | 1 | 11 | -0,65 % | ||
| AGIOS | 1 | 8 | -0,83 % | ||
| ARVINAS | 1 | 6 | +6,16 % | ||
| GILEAD SCIENCES | 1 | 5 | +0,34 % | ||
| REVOLUTION MEDICINES | 1 | 5 | -1,51 % | ||
| HARROW | 1 | 4 | -0,60 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares | 1 | The Motley Fool Australia | ||
| Sa | ZachXBT deckt auf, wie die US-Anwaltskanzlei Gerstein Harrow 71 Millionen Dollar aus gestohlenen Lazarus-Geldern an sich gerissen hat | 2 | Bitcoin.com News | ||
| Sa | DRINGEND: Biontech: Könnte die Aktie jetzt komplett einbrechen? - Was Sie über das Wochenende vorbereiten sollten | Hebelschein-Spekulant | |||
| Sa | Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? | 2 | The Motley Fool | ||
| Sa | Why Axsome Therapeutics Stock Jumped Over 20% in April | 3 | The Motley Fool | ||
| Sa | Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock | 1 | Insider Monkey | ||
| Sa | Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock | 3 | Insider Monkey | ||
| Sa | BridgeBio Pharma Inc. (BBIO): Billionaire Tom Steyer Admires Upside Potential of This Stock | 2 | Insider Monkey | ||
| Sa | Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This Stock | 1 | Insider Monkey | ||
| Sa | Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) | 3 | The Motley Fool | ||
| Sa | AMGEN INC: Stabilität als Ausgangspunkt | 3 | Maximilian Berger | ||
| Sa | Incyte: FDA Approves Jakafi XR In Myelofibrosis, Polycythemia Vera, And Graft-Versus-Host Disease | 435 | AFX News | WASHINGTON (dpa-AFX) - Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediate-... ► Artikel lesen | |
| Sa | Bioxyne vor dem Durchbruch? Trumps neues Dekret könnte Kurspotenzial für Psychedelika-Pioniere entfesseln | Small- & Micro Cap Investment | |||
| Sa | FDA approves Pfizer-Arvinas breast cancer pill Veppanu for advanced cases | 7 | Investing.com | ||
| Sa | Cathie Wood's ARK sells AMD stock, buys Roblox and Intellia | 45 | Investing.com | ||
| Fr | FDA genehmigt neue Jakafi-Formulierung von Incyte mit einmal täglicher Einnahme | 4 | Investing.com Deutsch | ||
| Fr | FDA approves Incyte's once-daily Jakafi XR formulation | 4 | Investing.com | ||
| Fr | Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease | 399 | Business Wire | Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi(ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily... ► Artikel lesen | |
| Fr | Stifel hebt Kursziel für Syndax Pharmaceuticals wegen positiver Therapie-Aussichten an | 15 | Investing.com Deutsch | ||
| Fr | Stifel raises Syndax Pharmaceuticals stock price target on therapy trajectory | 1 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.